Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.
News|Articles|June 27, 2026
Improving Recognition of Autonomic Dysfunction in Parkinson Disease: Insights With Jonathan Isaacson, MD; and Abhishek Lenka, MD, PhD
Fact checked by: Marco Meglio
Movement disorder experts Jonathan Isaacson, MD, and Abhishek Lenka, MD, PhD, discuss early identification and accurate diagnosis of autonomic dysfunction in Parkinson disease, highlighting emerging biomarkers and monitoring tools that may enable more personalized care.
Advertisement
Advertisement
Autonomic dysfunction is a common yet frequently underrecognized feature of Parkinson disease (PD), contributing to symptoms that can affect quality of life and may be associated with increased morbidity and mortality. Conditions such as orthostatic hypotension, supine hypertension, and pure autonomic failure often present with nonspecific symptoms, making diagnosis challenging and potentially delaying appropriate treatment.
Related to this article
An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.
The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
Interim phase 1b data showed that cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.
Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.
Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.
Advertisement
Advertisement